Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
37
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Corvus Pharmaceuticals Inc market cap is $844.37M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Corvus Pharmaceuticals Inc 52 week high is $26.95 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Corvus Pharmaceuticals Inc 52 week low is $6.39 as of November 20, 2026.
Corvus Pharmaceuticals Inc stock price today is $9.67.
Corvus Pharmaceuticals Inc stock price yesterday was $10.01.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Corvus Pharmaceuticals Inc's P/E ratio is -14.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Corvus Pharmaceuticals Inc P/B ratio is 4.0516.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Corvus Pharmaceuticals Inc 50-day moving average is $10.91.